Enfusion (ENFN) Stock Forecast & Price Target

$9.79 -0.09 (-0.91%)

(As of 11/15/2024 ET)

Enfusion - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 5 Analyst Ratings

Sell
3

Hold
1

Buy
1

Based on 5 Wall Street analysts who have issued ratings for Enfusion in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 5 analysts, 3 have given a sell rating, 1 has given a hold rating, and 1 has given a buy rating for ENFN.

Consensus Price Target

$9.40
-3.98% Downside

According to the 5 analysts' twelve-month price targets for Enfusion, the average price target is $9.40. The highest price target for ENFN is $11.00, while the lowest price target for ENFN is $8.00. The average price target represents a forecasted downside of -3.98% from the current price of $9.79.

Get the Latest News and Ratings for ENFN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Enfusion and its competitors.

ENFN Analyst Ratings Over Time

Type	Current Forecast 11/16/23 to 11/15/24	1 Month Ago 10/17/23 to 10/16/24	3 Months Ago 8/18/23 to 8/17/24	1 Year Ago 11/16/22 to 11/16/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)
Hold	1 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	4 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$9.40	$9.33	$9.33	$10.71
Forecasted Upside	-3.98% Downside	4.93% Upside	15.51% Upside	5.98% Upside
Consensus Rating	Reduce	Reduce	Reduce	Hold

Central Bank Abandons USD (Ad)

Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.

Click here now to get your free 'Protect Your Wealth' Guide.

ENFN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ENFN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Enfusion Stock vs. The Competition

Type	Enfusion	Computer and Technology Companies	S&P 500
Consensus Rating Score	1.60	2.67	2.50
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	-4.95% Downside	552.34% Upside	9.97% Upside
News Sentiment Rating	Positive News See Recent ENFN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
5/10/2024	Morgan Stanley 3 of 5 stars	Initiated Coverage	Overweight	$11.00	+21.95%
3/13/2024	Bank of America 4 of 5 stars	Boost Target	Underperform ➝ Underperform	$8.00 ➝ $9.00	-1.85%
2/28/2024	The Goldman Sachs Group 2 of 5 stars	Downgrade	Neutral ➝ Sell	$9.00 ➝ $8.00	-14.26%
1/30/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underweight	$11.00 ➝ $9.00	+5.88%
12/20/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$9.00 ➝ $10.00	+0.40%
11/7/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$9.00	+8.56%
11/16/2022	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$14.00	+4.56%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:29 AM ET.

ENFN Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Enfusion is $9.40, with a high forecast of $11.00 and a low forecast of $8.00.
: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 3 sell ratings, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" ENFN shares.
: According to analysts, Enfusion's stock has a predicted downside of -3.98% based on their 12-month stock forecasts.
: Analysts like Enfusion less than other "computer and technology" companies. The consensus rating for Enfusion is Reduce while the average consensus rating for "computer and technology" companies is Moderate Buy. Learn more on how ENFN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Central Bank Abandons USD (Ad)

Click here now to get your free 'Protect Your Wealth' Guide.

This page (NYSE:ENFN) was last updated on 11/15/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enfusion (ENFN) Stock Forecast & Price Target